Biotron Limited (BITRF)
Biotron Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Sydney, NSW, AU. The stock last traded at $0.04, up 0.00% on the session, giving a market capitalisation of $37.6M. On trailing twelve-month figures it carries a trailing P/E of -6.67, a net margin of 223061.1%. Its beta of -0.64 implies it has historically moved less than the broad market.
Biotron Limited is an Australian biotechnology firm focused on the development and market introduction of small-molecule compounds designed to combat various viral infections. The company's primary antiviral agent, BIT225, is currently undergoing Phase II clinical trials to assess its efficacy against SARS-CoV-2, HIV-1, and hepatitis C virus infections. Founded in 1999, Biotron Limited's main offices are situated in Sydney, Australia.
Biotron Limited is most often compared with the following Healthcare names: